As such, drugs targeting toxic PFPs could help limit the extent of infection, aid in preventing systemic spreading when a localized infection is present, and prevent toxic PFP-mediated tissue destruction (e.g., in S. pneumoniae or S. aureus pneumonia or clostridial myonecrosis). The gene discussed is PRF1; the disease is infection due to clostridium perfringens.